Today: 21 May 2026
AST SpaceMobile (ASTS) stock sinks as AT&T taps Amazon Leo for satellite connectivity
5 February 2026
2 mins read

AST SpaceMobile (ASTS) stock sinks as AT&T taps Amazon Leo for satellite connectivity

New York, Feb 5, 2026, 12:30 EST — Regular session

  • Shares of AST SpaceMobile fell during midday trading, adding to a turbulent week for stocks tied to the space sector.
  • AT&T’s latest collaboration with Amazon Leo has sharpened attention on how U.S. carriers plan to leverage satellite connections.
  • Investors are focused on AST’s upcoming launch window and whether telecom partners will increase or shift their capacity.

Shares of AST SpaceMobile dropped 7.8% to $95.45 by midday Thursday, fluctuating between $104.01 and $92.24 earlier. The Invesco QQQ ETF, which tracks the Nasdaq, slipped roughly 1.1%, with Amazon falling 3.9% and AT&T dipping 0.4%.

This move is crucial since AST’s narrative hinges on execution and backing from carriers. The company is developing a “direct-to-device” network, allowing regular phones to link with satellites sans extra gear. Investors have zeroed in on U.S. telecom partnerships as a major indicator.

AT&T, Amazon Web Services, and Amazon Leo announced Wednesday they’re stepping up collaboration on cloud migration, fiber connectivity, and satellite links. As part of the deal, AT&T will shift workloads to AWS Outposts, supply high-capacity fiber for AWS data centers, and tap into Amazon Leo’s low-Earth-orbit satellite network to broaden its coverage. Shawn Hakl, AT&T Business product chief, described fiber as “the foundation” of the initiative. Business Wire

In a separate interview, AWS product executive Amir Rao called the AT&T workload migration a move at “massive scale.” An AT&T spokesperson told Fierce that integrating Amazon Leo for fixed broadband won’t alter its existing relationship or plans with AST, which remains centered on direct-to-cell service for mobility users. Fierce Telecom

Investors are also questioning if Amazon’s satellite rollout will stay on schedule. Amazon Leo has formally requested a 24-month extension from the U.S. Federal Communications Commission to hit an interim deployment target for its planned 3,236-satellite network. The company pointed to launch delays and other setbacks. As of January, Amazon said it had 180 satellites in orbit and planned to reach roughly 700 by July 30, 2026.

Legal developments stirred the waters. On Feb. 3, Pomerantz LLP announced it’s probing claims for AST SpaceMobile investors. The firm’s alert referenced a Scotiabank downgrade from early January, which highlighted stiff competition from SpaceX’s Starlink, sluggish adoption rates, and delayed launches.

AST has a key date on the horizon that traders are focused on. The company announced that BlueBird 7, its next-gen satellite, is set to launch late February aboard Blue Origin’s New Glenn-3 from Cape Canaveral. Looking ahead to 2026, AST plans to maintain a steady launch pace—roughly one orbital mission every one to two months—aiming to deploy between 45 and 60 satellites by year-end. “This launch advances our mission to bring space-based cellular broadband connectivity to everyday smartphones,” said AST President Scott Wisniewski. Business Wire

The key question now: Is AT&T’s deal with Amazon Leo simply adding capacity, another option to tackle fixed broadband “dead zones,” or does it hint that carriers want multiple routes to space—and thus more bargaining power—as satellite-to-phone services develop?

The downside scenario is clear-cut: delays in launch schedules, technical glitches in orbit, or slower-than-expected carrier deployments would hit a stock priced for long-term revenue growth. Ongoing legal probes and evolving competitive disputes could also sustain both the premium and the stock’s volatility.

Next on the docket: the BlueBird 7 launch window set for late February, plus fresh updates from AT&T and AWS at Mobile World Congress in early March. All eyes will also be on the FCC as it reviews Amazon Leo’s extension request.

Stock Market Today

  • Stocks Climb as Oil Prices and Treasury Yields Drop Ahead of Nvidia Earnings
    May 20, 2026, 6:04 PM EDT. U.S. stocks surged with the Dow Jones up 1.31%, S&P 500 gaining 1.08%, and Nasdaq rising 1.54% on May 20, 2026. This followed a sharp decline in oil prices, with WTI crude down 5.66% at $98.26 per barrel, and Brent crude falling 5.63%. Lower oil prices came after reports of progress in Middle East peace talks. Treasury yields eased, with the 10-year yield dropping over 9 basis points, alleviating recent inflation concerns. Market focus shifts to Nvidia's Q1 earnings report, seen as a critical indicator for the AI sector and chip demand. Nvidia shares rose over 1% ahead of results, trading near a 20% gain for the year. Analysts caution that while expectations are muted, the report could influence the broader market sentiment significantly.

Latest articles

Xanadu Jumps 20% After Quantum Selloff, Filing Remains Over XNDU

Xanadu Jumps 20% After Quantum Selloff, Filing Remains Over XNDU

20 May 2026
Xanadu Quantum Technologies’ shares surged 20.4% to $14.13 Wednesday, rebounding after a sharp May decline. The company reported Q1 revenue of $2.83 million and a net loss of $20.6 million, with 43.3 million Class B shares outstanding and a prospectus covering up to 293.7 million more. Other quantum stocks also rose. Xanadu is in talks for up to $285 million in Canadian government support.
MicroAlgo Shares Surge 40% as Quantum Release Drives MLGO Spike

MicroAlgo Shares Surge 40% as Quantum Release Drives MLGO Spike

20 May 2026
MicroAlgo shares surged 39.95% to $5.36 after the company announced a quantum image-processing algorithm, with volume reaching 9.74 million shares versus a 447,270 average. The stock hit $6.87 intraday before slipping to $5.22 after hours. No customer deals, revenue targets, or product launch dates were disclosed. Market cap stood near $66.7 million at the close.
Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

20 May 2026
Immunovant shares jumped 35.3% to $35.56 after reporting 16-week data showing its drug IMVT-1402 produced ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% in difficult-to-treat rheumatoid arthritis. Roivant Sciences, its majority owner, rose 14.9%. No new safety signals were reported. The trial enrolled 170 patients, most of whom had failed two prior advanced therapies.
Why Lam Research (LRCX) stock is bouncing after a bruising 9% drop
Previous Story

Why Lam Research (LRCX) stock is bouncing after a bruising 9% drop

Dayforce stock (DAY) stops trading: $70 cash payout, delisting and S&P 500 exit in focus
Next Story

Dayforce stock (DAY) stops trading: $70 cash payout, delisting and S&P 500 exit in focus

Go toTop